F
Fengcai Zhu
Researcher at Centers for Disease Control and Prevention
Publications - 256
Citations - 9539
Fengcai Zhu is an academic researcher from Centers for Disease Control and Prevention. The author has contributed to research in topics: Vaccination & Medicine. The author has an hindex of 38, co-authored 205 publications receiving 6758 citations. Previous affiliations of Fengcai Zhu include Nanjing Medical University & Xiamen University.
Papers
More filters
Journal ArticleDOI
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Yanjun Zhang,Gang Zeng,Hongxing Pan,Changgui Li,Yaling Hu,Kai Chu,Weixiao Han,Zhen Chen,Rong Tang,Weidong Yin,Xin Chen,Yuansheng Hu,Xiao-Yong Liu,Cong-Bing Jiang,Jingxin Li,Minnan Yang,Yan Song,Xiangxi Wang,Qiang Gao,Fengcai Zhu +19 more
TL;DR: The primary safety endpoint was adverse reactions within 28 days after injection in all participants who were given at least one dose of study drug (safety population).
Journal ArticleDOI
Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial
Fengcai Zhu,Jun Zhang,Xuefeng Zhang,Cheng Zhou,Zhong-Ze Wang,Shoujie Huang,Hua Wang,Chang-Lin Yang,Han-Min Jiang,Jia-Ping Cai,Yi-Jun Wang,Xing Ai,Yuemei Hu,Quan Tang,Xin Yao,Qiang Yan,Yangling Xian,Ting Wu,Yimin Li,Ji Miao,Mun-Hon Ng,James Wai-Kuo Shih,Ningshao Xia +22 more
TL;DR: HEV 239 is well tolerated and effective in the prevention of hepatitis E in the general population in China, including both men and women age 16-65 years and no vaccination-related serious adverse event was noted.
Journal ArticleDOI
Co-infection with respiratory pathogens among COVID-2019 cases.
Xiaojuan Zhu,Yiyue Ge,Tao Wu,Kangchen Zhao,Yin Chen,Bin Wu,Fengcai Zhu,Baoli Zhu,Baoli Zhu,Lunbiao Cui +9 more
TL;DR: Bacterial co-infections were dominant in all COVID-19 patients, Streptococcus pneumoniae was the most common, followed by Klebsiella pneumoniae and Haemophilus influenzae, and the highest and lowest rates of co- Infections were found in patients aged 15–44 and below 15, respectively.
Journal ArticleDOI
Efficacy, Safety, and Immunogenicity of an Enterovirus 71 Vaccine in China
Fengcai Zhu,Wenbo Xu,Jielai Xia,Zhenglun Liang,Yan Liu,Xuefeng Zhang,Xiaojuan Tan,Ling Wang,Qunying Mao,Jun-Yu Wu,Yuemei Hu,Tianjiao Ji,Li-Fei Song,Liang Qi,Baomin Zhang,Gao Qiang,Jingxin Li,Shenyu Wang,Yuansheng Hu,Shanru Gu,Jianhua Zhang,Genhong Yao,Jian-Xiang Gu,Xushan Wang,Yuchun Zhou,Changbiao Chen,Minglei Zhang,Minquan Cao,Junzhi Wang,Hua Wang,Nan Wang +30 more
TL;DR: The EV71 vaccine provided protection against EV71-associated hand, foot, and mouth disease or herpangina in infants and young children.
Journal ArticleDOI
Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Fengcai Zhu,Fengcai Zhu,Fan-Yue Meng,Jingxin Li,Jingxin Li,Xiu-Ling Li,Qunying Mao,Hong Tao,Yun-Tao Zhang,Xin Yao,Kai Chu,Qing-Hua Chen,Yuemei Hu,Xing Wu,Pei Liu,Lin-Yang Zhu,Fan Gao,Hui Jin,Yi-Juan Chen,Yu-Ying Dong,Yong-Chun Liang,Nianmin Shi,Heng-Ming Ge,Lin Liu,Sheng-Gen Chen,Xing Ai,Zhen-Yu Zhang,Yu-Guo Ji,Fengji Luo,Xiao-Qin Chen,Ya Zhang,Li-Wen Zhu,Zhenglun Liang,Xin-Liang Shen +33 more
TL;DR: Evaluating the efficacy, safety, immunogenicity, antibody persistence, and immunological correlates of an inactivated alum-adjuvant EV71 vaccine in healthy children from four centres in China found it provides high efficacy, satisfactory safety, and sustained Immunogenicity.